Pfizer boosts China presence with US$350m biotech plant
Facility to be completed in 2018, will make biologics and cheaper versions
Add BT as a preferred sourceBeijing
PFIZER Inc will invest US$350 million in eastern China on a plant for biotechnology drugs, bolstering its presence in the world's second largest pharmaceutical market despite slowing economic growth in the country and rising pressure on prices for medicines.
The new facility in eastern Hangzhou city is expected to be completed in 2018 and will manufacture biologics, or complex medicines made from living organisms, as well as cheaper copycat versions known as biosimilars for patients in China and across the world, Pfizer said in an e-mailed statement Tuesday.
TRENDING NOW
MedPark’s assistant CEO runs a hospital where patients, physicians precede profits
E-commerce is killing ‘real’ commerce, says China’s beverage king Zhong Shanshan
Laos-China Railway picks up steam, but S-E Asian country struggles to capture gains
NDR 2026: Singapore to create new Western island to support 'new generation of industries'
